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of Science.Neurokinin 1 receptor signaling in endosomes mediates
sustained nociception and is a viable therapeutic
target for prolonged pain relief
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Typically considered to be cell surface sensors of extracellular signals, heterotrimeric GTP-bindingprotein (Gprotein)–
coupled receptors (GPCRs) control many pathophysiological processes and are the target of 30% of therapeutic
drugs. Activated receptors redistribute to endosomes, but researchers have yet to explore whether endosomal re-
ceptors generate signals that control complex processes in vivo and are viable therapeutic targets. We report that the
substance P (SP) neurokinin 1 receptor (NK1R) signals from endosomes to induce sustained excitation of spinal neu-
rons and pain transmission and that specific antagonism of the NK1R in endosomes with membrane-anchored drug
conjugates providesmore effective and sustained pain relief than conventional plasmamembrane–targeted antago-
nists. Pharmacological and genetic disruption of clathrin, dynamin, and b-arrestin blocked SP-induced NK1R endocy-
tosis and prevented SP-stimulated activation of cytosolic protein kinase C and nuclear extracellular signal–regulated
kinase, as well as transcription. Endocytosis inhibitors prevented sustained SP-induced excitation of neurons in spinal
cord slices in vitro and attenuated nociception in vivo. When conjugated to cholestanol to promote endosomal tar-
geting, NK1R antagonists selectively inhibited endosomal signaling and sustained neuronal excitation. Cholestanol
conjugation amplified and prolonged the antinociceptive actions of NK1R antagonists. These results reveal a critical
role for endosomal signaling of the NK1R in the complex pathophysiology of pain and demonstrate the use of en-
dosomally targeted GPCR antagonists.INTRODUCTION
Whereas acute pain allows avoidance of injury and is essential for sur-
vival, chronic pain accompanies disease (for example, inflammatory
diseases and neuropathies) and therapy (for example, chemotherapy),
afflicts 20% of individuals at some point of their lives, and is a major
cause of suffering (1). The mechanisms that underlie the transition be-
tween acute (physiological) and chronic (pathological) pain and that
sustain chronic pain are unknown. Current therapies for chronic pain
are often ineffective or produce unacceptable side effects. The opioid
epidemic, a leading cause of medication-induced death, highlights the
need for improved pain therapy (2).
With almost 1000 members in humans, heterotrimeric GTP-
binding protein (Gprotein)–coupled receptors (GPCRs) are the largestreceptor family, participate in most physiological and patho-
physiological processes, are the target of ~30% of therapeutic drugs
(3), and control all steps of pain transmission (1, 4). GPCRs at the
peripheral terminals of primary sensory neurons detect ligands from
inflamed and injured tissues, and GPCRs control the activity of
second-order spinal neurons that transmit pain signals centrally. Al-
though GPCRs are a major therapeutic target for chronic pain, most
GPCR-targeted drugs for pain have failed in clinical trials, often for
unknown reasons (4, 5).
GPCRs are conventionally viewed as cell surface receptors that de-
tect extracellular ligands and couple to G proteins, which trigger plas-
ma membrane–delimited signaling events (second messenger
formation, growth factor receptor transactivation, and ion channel
regulation). Activated GPCRs associate with b-arrestins (bARRs),
which uncouple receptors from G proteins and terminate plasma
membrane signaling. bARRs also couple receptors to clathrin and
adaptor protein-2 and convey receptors and ligands to endosomes
(6). Once considered merely a conduit for GPCR trafficking, endo-
somes are a vital site of signaling (4, 7, 8). bARRs recruit GPCRs and
mitogen-activated protein kinases to endosomes and thereby mediate
endosomal GPCR signaling (9, 10). Some GPCRs in endosomes acti-
vateGas G proteins, suggesting endosomal cyclic adenosinemonophos-
phate (cAMP)–dependent signaling (11, 12). GPCR/G protein/bARR
complexes also contribute to sustained signaling by internalized receptors
(13). Although a growing number of GPCRs can signal from endosomes,
the mechanisms and outcomes of endosomal signaling are incompletely
understood, and its relevance to complex pathophysiological processes
in vivo is unexplored. Drug discovery programs aim to identify ligands for1 of 15
SC I ENCE TRANS LAT IONAL MED I C I N E | R E S EARCH ART I C L Ecell surface GPCRs, and whether endosomal GPCRs are a therapeutic
target remains to be determined.
We examined the contributionof endocytosis of the neurokinin 1 re-
ceptor (NK1R) to substance P (SP)–mediated nociception. Painful
stimuli release SP from the central projections of primary sensory neu-
rons in the dorsal horn of the spinal cord, where SP induces endocytosis
of the NK1R in second-order neurons, which integrate nociceptive
signals (5, 14). The NK1R may also be internalized in pain-sensing re-
gions of the brain of patientswith chronic pain (5, 15).Wehypothesized
that endosomal signaling is a critical but unappreciated contributor to
pain transmission and that targeting NK1R antagonists to sites of endo-
somal signalingmight provide an effective route to pain relief. Thus, the
clinical failure of conventional NK1R antagonists for the treatment of
chronic pain and other chronic conditions associated with NK1R endo-
cytosis (5) might relate to their inability to target and antagonize the
NK1R within multiprotein signalosomes of acidified endosomes.RESULTS
Clathrin, dynamin, and bARRs mediate NK1R endocytosis
To quantify NK1R endocytosis, we used bioluminescence resonance
energy transfer (BRET) to assess NK1R proximity to bARRs and resi-
dent proteins of plasma membranes (KRAS) and early endosomal
membranes (RAB5A) in human embryonic kidney (HEK) 293 cells
(fig. S1A). SP (1 or 10 nM) increased NK1R–RLUC8/bARR1/2–yellow
fluorescent protein (YFP) BRET (fig. S1, B and C), which is consistent
with bARR-mediated NK1R endocytosis (16). SP decreased NK1R-
RLUC8/KRAS-Venus BRET and concomitantly increased NK1R-RLUC8/
RAB5A-Venus BRET (fig. S1, D to G), indicating NK1R endocytosis.
The dynamin inhibitor Dyngo-4a (Dy4) (17), the clathrin inhibitor
Pitstop-2 (PS2) (18), and adominant-negative versionof dynamin (K44E)
(19) inhibitedNK1R endocytosis, whereas inactive analogs (Dy4 inact and
PS2 inact) and wild-type (WT) dynamin had no effect. Dynamin K44E
increased the NK1R-RLUC8/bARR1/2-YFP BRET, suggesting that
dynamin-dependent translocation of theNK1R/bARR from the plas-
ma membrane to endosomes initiates NK1R/bARR dissociation (fig.
S1H).Dy4 andPS2 also inhibited endocytosis of fluorescentAlexa Fluor
568–SP in HEK-NK1R cells, causing retention in punctate structures
(fig. S1I). These structures may represent ligand/receptor clusters in in-
vaginated pits in cells treated with Dy4 or at the plasma membrane in
cells treatedwith PS2. Thus, bARRs, clathrin, and dynaminmediate SP-
induced NK1R endocytosis.
NK1R endocytosis mediates SP signaling in
subcellular compartments
To study the link between GPCR endocytosis and signaling in sub-
cellular compartments with high spatiotemporal fidelity, we expressed,
in HEK293 cells, the NK1R and fluorescence resonance energy transfer
(FRET) biosensors for cytosolic (CytoEKAR) or nuclear (NucEKAR)
extracellular signal–regulated kinase (ERK) activity, plasma membrane
(pmCKAR) or cytosolic (CytoCKAR) protein kinase C (PKC) activity,
and plasmamembrane (pmEpac2) or cytosolic (CytoEpac2) cAMP (fig.
S2A) (20). SP (1 nM) induced a gradual and sustained activation of nu-
clear ERK (Fig. 1, A to C) and a rapid and sustained activation of cyto-
solic PKC (Fig. 1, D to F) and cAMP (Fig. 1, G to I). SP rapidly and
transiently activated cytosolic ERK (fig. S2, B andC), did not affect plas-
mamembrane PKC (fig. S2, D andE), and increased plasmamembrane
cAMP (fig. S2, F and G). Inhibitors of clathrin (PS2) and dynamin
(Dy4) abolished SP stimulation of nuclear ERK (Fig. 1, A toC), cytosolicJensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 2017PKC (Fig. 1, D to F), and cytosolic cAMP (Fig. 1, G to I), indicating a
requirement for endocytosis. In contrast, PS2 andDy4 did not affect SP
activation of cytosolic ERK (fig. S2, B and C) or plasma membrane
cAMP (fig. S2, F and G), which do not require endocytosis, but ampli-
fied plasma membrane PKC activity (fig. S2, D and E). Expression of
dynamin K44E, but not dynamin WT, prevented SP stimulation of
nuclear ERK (Fig. 1, J to L). Dynamin K44E did not prevent SP stimu-
lation of cytosolic ERK but caused the response to become sustained
when compared to dynaminWT (fig. S2, H to J). Knockdown of dyna-
min-1 and clathrin heavy chain with small interfering RNA (siRNA)
(fig. S2, K and L) prevented SP activation of nuclear ERK (Fig. 1, M
and N).
Transcription is a major endpoint of GPCR signaling, including ac-
tivation of nuclear ERK. The b2-adrenergic receptor signals from en-
dosomes to regulate transcription (21). To investigate the contribution
of NK1R endocytosis to SP-stimulated transcription, we expressed in
HEK-NK1R cells a reporter encoding secreted alkaline phosphatase
(SEAP) under control of the serum response element (SRE) tran-
scription factor. SP (10 nM) stimulated SRE-SEAP secretion after 4
and 24 hours, indicating stimulated transcription (Fig. 1O). Dynamin
K44E abolished SP-stimulated transcription at both times. Dynamin
K44E reduced the efficacy but not the potency of SP-induced
transcription, measured after 24 hours (fig. S2M). Thus, NK1R endocy-
tosis is required for SP stimulation of transcription.
We have previously shown that bARRs mediate NK1R endosomal
signaling and nuclear ERK activation (9, 22, 23). To examine the con-
tribution of G proteins to endosomal NK1R signaling, we used BRET to
study SP-induced trafficking of Gaq subunits to early endosomes
containing RAB5A. SP (0.1 to 10 nM) decreased NK1R-RLUC8/
KRAS-Venus and increased NK1R-RLUC8/RAB5A-Venus BRET,
demonstrating endocytosis, and decreased Gaq-RLUC8/Gg2-Venus
BRET, consistent with G protein activation (Fig. 2, A to C, and fig.
S3, A to C). SP increased Gaq-RLUC8/RAB5A-Venus BRET, which
indicates Gaq translocation to early endosomes that contain the inter-
nalized NK1R (Fig. 2D and fig. S3D). In SP-stimulated cells, NK1R-
immunoreactivity (IR) and Gaq-IR colocalized with early endosomal
antigen 1 (EEA1)–IR (Fig. 2, E and F); IR was detected using immu-
nofluorescence and super-resolution microscopy.
The Gaq inhibitor UBO-QIC prevented SP activation of nuclear
ERK (Fig. 2G and fig. S3E), which also depends on bARRs and PKC
but not on epidermal growth factor receptor transactivation (9, 22, 23).
UBO-QIC, the phospholipase C (PLC) inhibitor U73122, and the Ca2+
chelator EGTA prevented activation of cytosolic PKC (Fig. 2H and
fig. S3F), which is consistent with a Gaq, PLC, and Ca
2+-dependent
PKC pathway. UBO-QIC, the PKC inhibitor GF109203X, and EGTA,
but not the Gas inhibitor NF449, prevented SP generation of cytosolic
cAMP (Fig. 2I and fig. S3G), supporting a role for Gaq-mediated ac-
tivation of Ca2+-dependent PKC in the generation of cAMP. UBO-QIC
did not affect NK1R endocytosis (fig. S3H). In addition to inhibiting
PKCa (4% control), GF109203X (Bis-1) also inhibits other kinases
(24), which may also contribute to SP signaling. These results sup-
port the hypothesis that SP and the NK1R signal from endosomes by
Gaq-mediated mechanisms to activate nuclear ERK and cytosolic
PKC and cAMP.
Endocytosis mediates sustained SP-evoked excitation of
spinal neurons
The NK1R mediates nociceptive transmission in second-order spinal
neurons, where painful stimuli induce SP release, NK1R endocytosis,2 of 15
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Fig. 1. NK1R endocytosis-dependent compartmentalized signaling. (A to I) Effect of inhibitors of dynamin (Dy4) and clathrin (PS2), and of inactive (inact) analogs, on SP-
induced spatiotemporal signaling profiles for nuclear ERK (NucEKAR) (A to C), cytosolic PKC (CytoCKAR) (D to F), and cytosolic cAMP (CytoEpac2) (G to I) measured in HEK293 cells
using FRET biosensors. (A, D, and G) Time course of responses. (B, E, and H). Representative ratiometric images and sensor localization. Max, response to positive controls. Yellow
arrows denote localization of FRET sensor andwhite arrows show the SP-stimulated signals in control cells and cells treatedwith Dy4 inact. (C, F, and I) Area under the curve (AUC)
of (A), (D), and (G). (J andK) Effect of dynaminWT (J) or dominant negative K44E (K) overexpression on the spatiotemporal profile of SP-induced nuclear ERK. (L) AUC of (J) and (K).
(M) Effect of clathrin heavy chain and dynamin-1 siRNA on the spatiotemporal profile of SP-induced nuclear ERK. (N) AUC of (M). (O) Effect of dynaminWT or K44E overexpression
on the SP-induced SRE-SEAP. *P < 0.05, **P < 0.01, ***P < 0.001, vehicle (Veh); ^^P < 0.01, ^^^P < 0.001, control to inhibitors. (A to N) Thirty to 354 cells, three to five experiments.
(O) n = 3 experiments. ANOVA, Tukey’s test (C, F, I, and N); Sidak’s test (L); Dunnett’s test (O).Jensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 2017 3 of 15
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SC I ENCE TRANS LAT IONAL MED I C I N E | R E S EARCH ART I C L Eand ERK activation (5, 14, 25). SP causes persistent NK1R-dependent
excitation of spinal neurons by unknownmechanisms (26). To evaluate
whether NK1R endosomal signaling mediates this sustained excitation,
we made cell-attached patch clamp recordings from NK1R-positive
neurons in lamina I of the dorsal horn in slices of rat spinal cord. SP
(1 mM, 5 min) stimulated NK1R-IR endocytosis in spinal neurons
(Fig. 3, A and B, and movies S1 to S4). Brief exposure to SP (1 mM,
2 min) triggered rapid-onset action potential firing that was sustained
after washout (Fig. 3, C to E). Dy4 but not Dy4 inact inhibited NK1R
endocytosis. Dy4 did not affect the initial onset of SP-induced firing
but prevented the sustained response, reducing both the firing rate and
firing time, whereas Dy4 inact had no effect. The SP-induced firing
rate (events per 2 min, normalized to rate at 2 min) was 342.1 ±
120.7 with Dy4 and 569.0 ± 187.6 with Dy4 inact [P < 0.05, analysis
of variance (ANOVA), Sidak’s test].
To define the signaling pathway that mediates SP-evoked excitation
of spinal neurons, slices were preincubated with inhibitors of mitogen-
activated protein kinase kinase (MEK) (U0126), PKC (GF109203X), or
vehicle (control). U0126 inhibited the SP-induced firing time of lamina
I neurons by 67.5 ± 8.3% (control: 10.01 ± 1.8 min, n = 10 cells from
eight rats; U0126: 3.2 ± 0.8 min, n = 6 cells from six rats; P < 0.05,
ANOVA,Dunn’s test) (Fig. 3, F toH). GF109203X reduced SP-induced
firing time of lamina I neurons by 56.8 ± 8.2% (control: 10.01 ± 1.8min,
n=10 cells from eight rats; GF109203X: 4.33 ± 0.82min, n=7 cells from
four rats; P < 0.05, ANOVA, Dunn’s test). U0126 and GF109203X re-
duced the number of SP-stimulated action potentials by 84 ± 5% and
61 ± 15%, respectively, compared to controls.
Dy4 did not affect the generation of excitatory postsynaptic currents
(EPSCs) in lamina I/IIo neurons in response to primary afferent stim-
ulation (Fig. 3, I and J). PS2 andDy4 did not affect capsaicin-stimulated
release of SP or calcitonin gene–related peptide (CGRP) from segments
of mouse dorsal spinal cord (Fig. 3, K and L). Thus, NK1R endocytosis
and resultant ERK and PKC signaling mediate sustained SP-induced
firing of spinal neurons. The effects of dynamin and clathrin inhibitors
in the spinal cord are unrelated to changes in glutaminergic-mediated
fast synaptic transmission or the exocytosis of neuropeptides.
Clathrin, dynamin, and bARRs mediate NK1R endocytosis
and nociception in vivo
To determine the involvement of dynamin and clathrin in NK1R endo-
cytosis in vivo, we injected Dy4, PS2, inactive analogs, or vehicle intra-
thecally (L3/L4) to rats. After 30 min, vehicle or capsaicin was
administered by intraplantar injection. The spinal cord was removed
10 min later, and the NK1R was localized by immunofluorescence
and confocal microscopy. In vehicle-treated control rats, the NK1R-
IR was mostly at the plasma membrane of lamina I neurons (%
NK1R-IR within 0.5 mm of plasma membrane, 80.7 ± 1.6; n = 3 rats,
6 neurons analyzed per rat) (Fig. 4, A andC, andmovie S5). Intraplantar
injection of capsaicin stimulated NK1R endocytosis (42.1 ± 5.6; P =
0.0027 to control, Student’s t test) (movie S6). Intrathecal injection of
Dy4 or PS2, but not inactive analogs, inhibited capsaicin-stimulated
NK1R endocytosis [Dy4 (59.6 ± 0.2) versus Dy4 inact (49.9 ± 0.8), P =
0.0004 (Student’s t test); PS2 (69.0 ± 1.1) versus PS2 inact (51.9 ±
1.3), P = 0.0135 (Student’s t test)] (movies S7 to S10 and Fig. 4, A
and C). Painful peripheral stimuli activate ERK in NK1R-expressing
spinal neurons, which contributes to hyperalgesia (25). Intraplantar
capsaicin stimulated ERK phosphorylation in lamina I/II dorsal horn
neurons (Fig. 4, B and D). Dy4 or PS2 prevented capsaicin-stimulated ERK
activation in spinal neurons. Thus, painful stimuli induce clathrin- andJensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 2017dynamin-dependent NK1R endocytosis in spinal neurons, which is re-
quired for ERK signaling.
Does NK1R endocytosis in spinal neurons mediate pain transmis-
sion? To evaluate the importance of the NK1R, clathrin, and dynamin
for nociception, we injected vehicle, NK1R antagonist SR140,333 (27),
Dy4, PS2, or inactive analogs intrathecally (L3/L4) tomice. After 30min,
vehicle or capsaicin was administered by intraplantar injection into one
hindpaw. Withdrawal responses were measured to stimulation of the
plantar surface of the ipsilateral (injected) and contralateral (nonin-
jected) hindpaws with von Frey filaments, and edema was assessed by
measuring thickness of the ipsilateral paw. In vehicle (intrathecal)–treated
mice, capsaicin caused mechanical allodynia and edema for 4 hours.
SR140,333 caused a partial and transient inhibition of capsaicin-induced
allodynia, whereas Dy4 and PS2, but not inactive analogs, caused a large
and sustained inhibition of allodynia (Fig. 4E and fig. S4A). Paw edema
was unaffected, confirming that after intrathecal injection, the drugs act
locally in the spinal cord (fig. S4B).
Dy4 and PS2 did not affect withdrawal responses of the contralateral
paw or rotarod latency, suggesting normalmotor behavior (Fig. 4, F and
G). Intrathecal Dy4 also inhibited capsaicin-evoked mechanical allody-
nia in rat, which supports a role for dynamin in nociception in different
species (fig. S4C).
Intrathecal injection of dynamin-1 siRNA knocked down dynamin-
1–IR (fig. S4D) and inhibited capsaicin-evoked allodynia after 24
and 48 hours in mice (Fig. 4H and fig. S4E). Intrathecal bARR1/2
siRNA knocked down bARR1/2 mRNA (fig. S4F) and inhibited
capsaicin-evoked allodynia at 36 hours (Fig. 4I). siRNAs did not affect
withdrawal responses of the contralateral paw (fig. S4, G and H),
consistent with normal motor function.
Endocytosis and subsequent recycling mediate resensitization and
sustained signaling of several GPCRs, including the NK1R (28). Thus,
the antinociceptive actions of endocytic inhibitors could be due to dis-
rupted resensitization of plasmamembrane signaling rather than to im-
paired endosomal signaling. Endothelin-converting enzyme-1, which is
coexpressed with the NK1R in spinal neurons (22), degrades SP in en-
dosomes and thereby promotes recycling and resensitization of the
NK1R (29). However, intrathecal injection of SM-19712, an inhibitor
of endothelin-converting enzyme-1 that prevents NK1R recycling and
resensitization (29), had no effect on capsaicin-induced allodynia (Fig.
4J). These results suggest that the analgesic actions of endocytic inhibi-
tors are unrelated to disrupted resensitization. Consistent with a role for
NK1R endocytosis and bARRs in SP-evoked nuclear ERK signaling (9),
intrathecal MEK inhibitor U0126 inhibited capsaicin-evoked allodynia
(Fig. 4K) (25).
The effects of inhibitors of dynamin and clathrin on non-
inflammatory and inflammatory pain were examined. Intrathecal
injection of Dy4 and PS2 blunted both the early (noninflammatory)
and late (inflammatory) phases of the nocifensive response to intra-
plantar formalin (Fig. 4L).When injected intrathecally 36 hours after
intraplantar injection of complete Freund’s adjuvant (CFA), which
causes sustained inflammatory pain, inhibitors of dynamin and
clathrin reversed preexisting mechanical hyperalgesia (Fig. 4M).
The NK1R was robustly internalized in spinal neurons of mice after
intraplantar injection of capsaicin, formalin, and CFA (fig. S5, A to
D). Intrathecal injection of Dy4 prevented capsaicin- and formalin-
induced NK1R endocytosis and reversed CFA-induced NK1R endo-
cytosis. These results suggest that clathrin and dynamin mediate
pain-evoked endocytosis of NK1R in spinal neurons, which is re-
quired for nociception.5 of 15
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To substantiate involvement of
NK1R endocytosis in nocicep-
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logical approach to inhibit
NK1R/bARR interactions and
NK1R endocytosis. G protein
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a control peptide, suggest-
ing effective disruption of
NK1R/bARR interactions
(Fig. 5, F and G). When
injected intrathecally, in-
hibitors of NK1R/bARR
interactions suppressed
capsaicin-evoked allody-
nia and formalin-induced nociceptive behavior and reversed CFA-
induced hyperalgesia (Fig. 5, H to J). Together, these results support
a role for bARR-mediated NK1R endocytosis and endosomal signaling
in nociception.Jensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 2017Lipid conjugation delivers NK1R antagonists to endosomes
and selectively blocks sustained endosomal signals
We observed that clathrin, dynamin, and bARR inhibitors and siRNA,
including selective inhibitors of NK1R/bARR interactions, suppress0 1 2 3 4
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transcription, and neuronal excitability, and have antinociceptive
actions. These findings support the hypothesis that endosomal
NK1R signaling underlies sustained neuronal excitation and nocicep-
tion. Thus, selective antagonism of endosomal receptors could be
an effective treatment for pain. To investigate this possibility and
to provide direct evidence for the importance of endosomal signaling
for nociception, we devised an approach to deliver and concentrate
GPCR antagonists in early endosomes.
Lipid conjugation anchors drugs at membrane surfaces and pro-
motes endosomal delivery (31). We synthesized tripartite probes com-
posed of cholestanol (Chol; promotes membrane insertion and
anchoring) or ethyl ester (control; no membrane anchoring), a flexible
polyethylene glycol (PEG) linker, and a cargo of either cyanine 5 (Cy5)
for localization or spantide I (Span), a peptidicmembrane–impermeant
NK1R antagonist (Fig. 6A) (32). In addition, we synthesized a probe
incorporating Span and Cy5 (Span-Cy5-Chol). When incubated with
HEK293 cells, Cy5-Chol inserted into the plasma membrane within
5 min, whereas Cy5–ethyl ester remained entirely extracellular (Fig. 6B
and movies S11 and S12). After 4 hours of continuous incubation,
Cy5-Chol was concentrated in RAB5A-positive early endosomes,
although Cy5-Chol was also detected at the plasma membrane
(Fig. 6C). When incubated with HEK-NK1R–green fluorescent protein
(GFP) cells for 4 hours, Cy5-Chol also colocalized with NK1R-GFP in
endosomes (cells were stimulated with SP to induce NK1R endocytosis)
(Fig. 6C). When HEK-NK1R–GFP cells were pulse-incubated with
Cy5-Chol for 30 or 60min, washed, and allowed to recover for 4 hours,
Cy5-Chol was gradually removed from the plasma membrane and ac-
cumulated in NK1R-GFP–positive endosomes, although some probe
remained at the plasma membrane (fig. S7, A and C). Cy5–ethyl ester
was not taken up by cells after pulse incubation (fig. S7B). Quantifica-
tion of Cy5-Chol uptake after a 30-min pulse incubation indicated that
69% of cell-bound probe was internalized at 4 hours and 79%was inter-
nalized at 8 hours after washing (fig. S7D). After pulse incubation, Cy5-
Span-Chol trafficked to NK1R-GFP–positive endosomes (Fig. 6C). Dy4
inhibited uptake of Chol-conjugated tripartite probes, consistent with
constitutive dynamin-mediated endocytosis (fig. S7E).
We used FRET to quantify association of tripartite probes with the
NK1R in endosomes. NK1R with extracellular N-terminal SNAP-Tag
was expressed in HEK293 cells, and cell surface NK1R was labeled with
membrane-impermeant SNAP–Surface-549 (SNAP-549). SP (10 nM,
30 min) evoked translocation of SNAP-549–NK1R to endosomes
(Fig. 6D). Cells were treated with Cy5-Chol, and FRET between
SNAP-549–NK1R and Cy5-Chol was measured in regions of interest
within the cytosol. Cy5-Chol/SNAP-549–NK1R FRET was detected
after 5min and increased for 60min (Fig. 6, D and E, andmovie S13).
FRET was not detected in control cells lacking NK1R (Fig. 6E).
Span-Chol antagonized SP [3 nM; 80% effective concentration
(EC80)]–stimulated Ca
2+ signaling in HEK-NK1R cells [minus log of
half maximal inhibitory concentration (pIC50), 8.23 ± 0.21 (Span)
and 8.44 ± 0.29 (Span-Chol)] and thus retained activity. Because the
tripartite probe was concentrated in endosomes after 4 hours, we
examined NK1R endosomal signaling 4 hours after preincubation with
antagonists. When HEK-NK1R cells were preincubated with Span-
Chol, Span, or SR140,333 for 30min and then immediately challenged
with SP, all antagonists blocked nuclear ERK (Fig. 6, F and H) and
cytosolic ERK (fig. S8, A andC) activity, indicating effective antagonism
of cell surface NK1R.When cells were pulse-incubated with antagonists
for 30 min, washed, and stimulated with SP 4 hours later (to allowJensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 2017lipidated antagonists to concentrate in endosomes), Span-Chol alone
inhibited nuclear ERK (derives from endosomal NK1R) (Fig. 6, G
andH), andno antagonist inhibited cytosolic ERK (derives fromplasma
membrane NK1R) (fig. S8, B and C). Span-Chol also prevented SP-
induced transcription. HEK-NK1R cells were incubated with Span or
Span-Chol for 30 min, washed, recovered for 4 hours, and then stimu-
latedwith SP for 20 hours. Span-Chol abolished SP-stimulated SRE-SEAP
secretion (derives from endosomal NK1R), whereas unconjugated Span
was ineffective (Fig. 6I). However, when continuously incubated with
antagonists, both Span-Chol andSpan inhibited transcription. Span-Chol
did not affect isoprenaline-induced activation of nuclear ERK, which is
mediated by the endogenous b2-adrenergic receptor (fig. S8D). Thus,
the effects of tripartite antagonists are not mediated by a nonspecific
disruption of endosomal signaling.
The results show that lipid conjugation promotes the effective deliv-
ery and retention of antagonists to endosomes containing the NK1R.
After pulse incubation, Span-Chol caused sustained and selective antag-
onism of endosomal but not plasma membrane NK1R. Unconjugated
Span and SR140,333, a potent small-molecule antagonist, were unable
to effectively inhibit persistent NK1R signaling in endosomes.
Endosomally targeted NK1R antagonists block nociception
To assess whether antagonismof the endosomalNK1R blocks sustained
SP-induced excitation of spinal neurons, we incubated slices of rat spi-
nal cord with Span-Chol or Span for 60 min, washed them, and chal-
lenged them with SP 60 min later. In vehicle- or Span-treated slices, SP
caused brisk firing that was sustained after washout (Fig. 7, A to C). As
observed with endocytic inhibitors, Span-Chol did not suppress the ini-
tial excitation but prevented sustained excitation. The SP-induced firing
rate (normalized to 2min, events per 2 min) was 196.6 ± 81.6 for Span-
Chol and 242.6 ± 95.9 for Span (P < 0.05, ANOVA, Sidak’s test).
To evaluate whether endosomal targeting improves the efficacy and
duration of action of NK1R antagonists for the treatment of pain, we
administered cholestanol-conjugated or conventional antagonists by in-
trathecal injection 3 hours before intraplantar injection of capsaicin.
This time was selected to allow endosomal accumulation of lipidated
antagonists. When Cy5-Chol was injected intrathecally, probe was de-
tected in laminae I to III neurons after 6 hours, confirming delivery and
retention in pain-transmitting neurons (Fig. 7D). Cy5-Chol did not af-
fect nociception, which excludes nonspecific actions of cholestanol (Fig.
7E). Span-Chol, but not Span or SR140,333, inhibited capsaicin-evoked
mechanical allodynia (Fig. 7E).When administered 30min after capsa-
icin, intrathecal Span was transiently antinociceptive, whereas Span-
Chol caused a delayed (3 hours), persistent (6 hours), and substantial
(>50%) antinociception (Fig. 7F).
The small-molecule NK1R antagonist L-733,060 (33) conjugated to
Chol antagonized SP (3 nM; EC80)–stimulated Ca
2+ signaling in HEK-
NK1R cells [% inhibition against 1 nMSP: 40.8 ± 8.9 (10 nML-733,060)
and 71.1 ± 9.2 (10 nM L-733,060-Chol)] and thus retained activity.
When injected intrathecally 3 hours before intraplantar capsaicin,
L-733,060–Chol was antinociceptive from 1 to 4 hours, whereas L-733,060
was antinociceptive only at 1 hour (Fig. 7G).
When injected intrathecally 3 hours before intraplantar formalin,
Span-Chol inhibited both phases of nocifensive behavior more com-
pletely than Span or SR140,333 (Fig. 7H). When injected intrathecally
36 hours after intraplantar CFA, Span-Chol inhibited mechanical
hyperalgesia from 1 to 6 hours, whereas the antinociceptive actions
of Span and SR140,333 were minor and transient for Span (Fig. 7, I
and J).8 of 15
SC I ENCE TRANS LAT IONAL MED I C I N E | R E S EARCH ART I C L EThe enhanced potency and duration of action of lipidated antago-
nists could be due to improved metabolic stability rather than to ap-
propriate targeting of endosomal NK1R. Membrane peptidases
rapidly degrade neuropeptides, including SP, and could also degrade
peptidic antagonists (5). Membranes prepared from mouse spinalJensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 2017cord rapidly degraded SP, but not Span or Span-Chol (Fig. 7K). Span
and Span-Chol were also stable in human cerebrospinal fluid (Fig.
7L). These results suggest that enhanced stability does not account
for the sustained antinociceptive actions of cholestanol-conjugated
antagonists.0
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intrathecally administered control and NK1R peptides on capsaicin-induced mechanical allodynia (H), formalin-evoked nocifensive behavior (I), and CFA-induced mechanical
hyperalgesia (J) in mice. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 to control. ANOVA, Sidak’s test (D and G); Dunnett’s test (H to J).9 of 15
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Our results support a reinter-
pretation of the notion that the
primary physiological actions of
GPCRs in vivo are mediated by
cell surface receptors. By study-
ing the NK1R as a prototypical
GPCR that traffics to endo-
somes, we show that endosomal
receptors convey sustained
signals that underlie excitation
and nociceptive transmission
in spinal neurons and that tar-
geting these receptors in endo-
somes is required for optimal
pharmacological intervention.
We report that endosomal
GPCRs generate a spectrum of
signals in subcellular compart-
ments. Clathrin and dynamin
disruption prevented NK1R en-
docytosis and inhibited activa-
tion of nuclear ERK, cytosolic
PKC, and cytosolic cAMP. Dy-
namin inhibitors also blocked
SP-induced transcription,
which is likely mediated by nu-
clear ERK. AC-terminally trun-
cated mutant, NK1Rd311, was
also unable to internalize, acti-
vate nuclear ERK, or stimulate
transcription. Gaq inhibition
blocked NK1R endosomal sig-
nals, and endosomes contained
both activated NK1R and Gaq.
Our results are consistent with
the hypothesis that the NK1R
in endosomes signals by Gaq-
dependent processes that acti-
vate nuclear ERK, cytosolic
PKC, and cytosolic cAMP to
cause nociception (Fig. 8A and
movie S14). By delivering acti-
vated NK1R to endosomes and
serving as a scaffold for sig-
naling complexes, bARRs facili-
tate these signals (9, 22, 23). Our
findings add to the growing
number of GPCRs, including
b2-adrenergic and thyroid-
stimulating hormone receptors
(11, 12), known to signal from
endosomes by G protein–
dependent processes, and pro-
vide in vivo evidence that this
endosomalmechanism is phys-
iologically relevant.
Together, our findings sug-
gest that endosomal NK1R0 1 2 3 4
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Fig. 7. Antagonism of endosomal NK1R in spinal cord slices and in vivo.
(A to C) Effects of tripartite antagonists on SP-induced firing of rat spinal neurons.
(A) Representative traces. (B) Firing rate normalized to 2 min. (C) Firing dura-
tion to last action potential. Six to seven neurons per group from n = 5 to 18 rats.
(D) Localization of Cy5-Chol (arrows, red) and DAP (blue) in superficial laminae
(L) 6 hours after intrathecal injection in mouse. Top panel shows phase contrast
superimposed on a fluorescence image; bottom panels show fluorescence images.
White box denotes magnified region. (E to J) Effects of intrathecally administered
Cy5-Chol, SR140,333 (SR), Span, Span-Chol, L-733,066 (L733), or L-733,0660–Chol on
nociception in mice. (E to G) von Frey withdrawal responses of capsaicin-injected paw. (H) Nocifensive behavior after intraplantar
formalin. (I and J) von Frey withdrawal responses of CFA-injected paw. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, to control.
(K) Kinetics of degradation of SP, Span, and Span-Chol by membranes prepared from mouse spinal cord (n = 3). (L) Kinetics of
degradation of Span and Span-Chol in human cerebrospinal fluid. n = 2, mean ± SD. ANOVA, Sidak’s test (B); Dunn’s test (C); Dunnett’s
test (E to J).11 of 15
SC I ENCE TRANS LAT IONAL MED I C I N E | R E S EARCH ART I C L Esignaling is necessary for sustained excitation of spinal neurons and noci-
ceptive transmission in the spinal cord, reveal a vital link between endo-
somal signaling and nociception, and provide information about the
contribution of clathrin and dynamin to SP-induced excitation of spinal
neurons and nociceptive transmission (Fig. 8B). The observations that dy-
namin and clathrin inhibitors attenuate NK1R endocytosis in spinal neu-
rons and suppress neuronal excitation and nociception are consistent with
a role for NK1R endocytosis in pain. The finding that selective disruption
ofNK1R-bARR interactionsusingmembrane-permeant peptides and spe-
cific antagonism of endosomalNK1Rwith lipidated antagonists effectively
suppress neuronal excitation and nociception in several models provides
direct support for a major contribution of the endosomal NK1R to pain.
The discovery that endosomes are platforms for compartmentalized
GPCR signaling that underlies pathophysiologically important pro-
cesses in vivo has therapeutic implications. Delivery of antagonists to
endosomes might facilitate the disruption of sustained signals from en-
dosomal GPCRs that underlie disease and could provide enhanced ef-
ficacy and selectivity for treating pain (Fig. 8C). The accumulation of
tripartite probes in NK1R-positive endosomes demonstrates the feasi-
bility of endosomal delivery. The capacity of Span-Chol and L-733,060–
Chol, but not unconjugated antagonists, to specifically antagonize en-
dosomalNK1R signaling and sustained excitation of spinal neurons and
to cause prolonged andmore effective antinociception demonstrates the
importance of endosomal signaling for pain and illustrates the thera-
peutic utility of endosomally directed drugs.
Limitations of the use of pharmacological inhibitors of endocytosis
include the widespread roles of dynamin and clathrin in vesicularJensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 2017transport and synaptic transmission (34, 35) and possible off-target
actions of dynamin inhibitors (36). Thus, the actions of clathrin and
dynamin inhibitors on excitation of spinal neurons and onnociceptive
behavior might be unrelated to impaired NK1R signaling in endo-
somes and instead due to disrupted endocytosis or exocytosis of other
GPCRs, ion channels, and transmitters that control pain transmission,
or an artifact of abnormal motor function. However, clathrin and dy-
namin inhibitors did not affect fast synaptic transmission in the spinal
cord or capsaicin-evoked neuropeptide release from spinal terminals
of nociceptors and had no effect onmotor coordination in vivo. These
results suggest that synaptic transmission and vesicular transport were
unaffected. The finding that dynamin 1 knockdown in the spinal cord
also inhibited nociception suggests that off-target actions of dynamin
inhibitors do not account for their antinociceptive properties. The ob-
servation that inhibitors of NK1R-bARR interactions and lipidated
NK1R antagonists replicate the antinociceptive effects of endocytosis
inhibitors supports a role for NK1R signaling in endosomes for noci-
ception. Additional studies will be required to assess the selectivity of
peptide inhibitors of NK1R-bARR interactions. The antinociceptive
actions of lipidated NK1R antagonists are unlikely to be related to
enhanced stability, given the similar rate of metabolism of un-
conjugated and cholestanol-conjugated spantide, although detailed
pharmacokinetic studies will be required to define the tissue
distribution and degradation of lipidated NK1R antagonists in vivo.
Evaluation of the therapeutic value of cholestanol-conjugated NK1R
antagonists will require investigation of their potency and efficacy in
disease-relevant models of pain.Endosome
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Fig. 8. Endosomal platforms for signaling pain. (A) Nociceptive signaling. NK1R
couples to Gaq (1), PLC-dependent Ca
2+ mobilization (2), and a disintegrin and metal-
loproteinase (ADAM)–dependent epidermal growth factor receptor (EGFR) transactiva-
tion (3), which stimulates cytosolic ERK (4). Ca2+ activates PKC, which stimulates
adenylyl cyclase (AC) to produce plasma membrane cAMP (5). GRK-phosphorylated
NK1R interacts with bARRs (6), which scaffold clathrin and adaptor protein 2 (AP2),
leading to SP/NK1R endocytosis (7). Endosomal SP/NK1R (8) stimulates cytosolic PKC
activity, cytosolic cAMP, and nuclear ERK activity (9), which drive neuronal excitation
and nociceptive transmission. (B) Antinociception, endocytic inhibitors. Inhibition of
dynamin (1), clathrin (2), or bARRs (3) prevents SP/NK1R endocytosis, endosomal
signaling, and nociceptive transmission. (C) Antinociception, tripartite antagonists. Tri-
partite antagonists incorporate into the plasmamembrane (1) and traffic to endosomes
(2), where they suppress SP/NK1R nociceptive signaling.12 of 15
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chronic inflammatory and neurological diseases that are associated
with persistent SP release (5). We propose that the inability of
conventional antagonists to effectively target the NK1R in endosomes,
where the receptor assembles a multiprotein signalosome in an acidic
environment, contributes to their lack of clinical success (5). Our
study suggests that therapeutic targeting of endosomal GPCRs is a
paradigmof drug delivery that offersmore effective and selective treat-
ments for pathophysiological conditions, including chronic pain.MATERIALS AND METHODS
See the Supplementary Materials for full details of Materials and
Methods.
Study design
The study was designed to examine the contribution of SP-induced en-
docytosis of the NK1R to signal transduction in subcellular compart-
ments, excitation of spinal neurons, and nociception. Endocytosis of
the NK1R was examined in HEK293 cells by using BRET to assess
the proximity between the NK1R and proteins resident in the plasma
membrane and early endosomes and by localizing fluorescent SP by
confocal microscopy. BRET was also used to examine the assembly of
signaling complexes, which were localized in endosomes by immuno-
fluorescence and super-resolution microscopy. Signaling in subcellular
compartments of HEK293 cells was studied by expressing genetically
encoded FRETbiosensors, which allowed analysis of signalingwith high
spatial and temporal fidelity. NK1R endocytosis was studied in spinal
neurons in slice preparations and in vivo by immunofluorescence and
confocal microscopy. To examine the excitation of pain-transmitting
neurons, cell-attached patch clamp recordings were made from
second-order neurons in slices of rat spinal cord. Nociceptive behavior
was evaluated in conscious mice after intraplantar administration of
capsaicin, formalin, or CFA. To examine the contribution of NK1R en-
docytosis to signaling, neuronal excitation, and nociception, HEK293
cells, rat spinal cord slices, or mice were treated with pharmacological
or genetic inhibitors of clathrin, dynamin, or bARRs, or with peptide
inhibitors ofNK1R/bARR interactions. Peptidic and small-molecule an-
tagonists of the NK1R were conjugated to the lipid cholestanol, which
facilitated endosomal targeting and retention of antagonists. Cholestanol-
conjugated antagonists were used to directly evaluate the contribution of
NK1R signaling in endosomes to SP-induced compartmentalized
signaling in HEK293 cells, excitation of spinal neurons, and nociception.
Institutional Animal Care and Use Committees approved all studies.
Statistical analyses
Data are presented as means ± SEM, unless noted otherwise. Differ-
ences were assessed using Student’s t test for two comparisons. For
multiple comparisons, differences were assessed using one- or two-
way ANOVA followed by Dunnett’s multiple comparison test, Tu-
key’s multiple comparison test, Sidak’s multiple comparisons test, or
Dunn’smultiple comparisons test. Table S1 provides full details of sta-
tistical tests and replicates for each experiment.SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/9/392/eaal3447/DC1
Materials and Methods
Fig. S1. Clathrin- and dynamin-dependent NK1R endocytosis.
Fig. S2. NK1R compartmentalized signaling.Jensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 2017Fig. S3. G protein–dependent NK1R signaling in endosomes.
Fig. S4. Nociception and inflammation in vivo.
Fig. S5. NK1R endocytosis in spinal neurons in vivo.
Fig. S6. NK1Rd311 expression and trafficking.
Fig. S7. Uptake of tripartite probes.
Fig. S8. Effects of NK1R tripartite antagonists on ERK signaling.
Fig. S9. Synthesis and analysis of Span-Chol and Span–ethyl ester.
Fig. S10. Synthesis and analysis of L-733,060-Chol.
Table S1. Statistical analyses and cell replicates.
Movie S1. Three-dimensional projections of NK1R-IR in neurons in spinal cord slices incubated
with Dy4 inact and vehicle.
Movie S2. Three-dimensional projections of NK1R-IR in neurons in spinal cord slices incubated
with Dy4 inact and SP.
Movie S3. Three-dimensional projections of NK1R-IR in neurons in spinal cord slices incubated
with Dy4 and vehicle.
Movie S4. Three-dimensional projections of NK1R-IR in neurons in spinal cord slices incubated
with Dy4 and SP.
Movie S5. Three-dimensional projections of NK1R-IR in neurons in spinal cord 10 min after
intraplantar injection of vehicle.
Movie S6. Three-dimensional projections of NK1R-IR in neurons in spinal cord 10 min after
intraplantar injection of capsaicin.
Movie S7. Three-dimensional projections of NK1R-IR in neurons in spinal cord 10 min after
intraplantar injection of capsaicin, with Dy4 injected before capsaicin.
Movie S8. Three-dimensional projections of NK1R-IR in neurons in spinal cord 10 min after
intraplantar injection of capsaicin, with Dy4 inact injected before capsaicin.
Movie S9. Three-dimensional projections of NK1R-IR in neurons in spinal cord 10 min after
intraplantar injection of capsaicin, with PS2 injected before capsaicin.
Movie S10. Three-dimensional projections of NK1R-IR in neurons in spinal cord 10 min after
intraplantar injection of capsaicin, with PS2 inact injected before capsaicin.
Movie S11. Plasma membrane incorporation and endocytosis of Cy5-cholestanol by HEK293
cells.
Movie S12. Lack of uptake of Cy5–ethyl ester by HEK293 cells.
Movie S13. Time lapse images showing FRET between SNAP-549-NK1R and Cy5-Chol.
Movie S14. Animation showing SP-induced assembly of endosomal signaling platform for pain
transmission.
References (37–54)REFERENCES AND NOTES
1. A. I. Basbaum, D. M. Bautista, G. Scherrer, D. Julius, Cellular and molecular mechanisms of
pain. Cell 139, 267–284 (2009).
2. B. Han, W. M. Compton, C. M. Jones, R. Cai, Nonmedical prescription opioid use and use
disorders among adults aged 18 through 64 years in the United States, 2003-2013.
JAMA 314, 1468–1478 (2015).
3. M. Audet, M. Bouvier, Insights into signaling from the b2-adrenergic receptor structure.
Nat. Chem. Biol. 4, 397–403 (2008).
4. P. Geppetti, N. A. Veldhuis, T. Lieu, N. W. Bunnett, G protein-coupled receptors: Dynamic
machines for signaling pain and itch. Neuron 88, 635–649 (2015).
5. M. S. Steinhoff, B. von Mentzer, P. Geppetti, C. Pothoulakis, N. W. Bunnett, Tachykinins
and their receptors: Contributions to physiological control and the mechanisms of
disease. Phys. Rev. 94, 265–301 (2014).
6. S. M. DeWire, S. Ahn, R. J. Lefkowitz, S. K. Shenoy, b-Arrestins and cell signaling. Annu. Rev.
Physiol. 69, 483–510 (2007).
7. R. Irannejad, M. von Zastrow, GPCR signaling along the endocytic pathway. Curr. Opin.
Cell Biol. 27, 109–116 (2014).
8. J. E. Murphy, B. E. Padilla, B. Hasdemir, G. S. Cottrell, N. W. Bunnett, Endosomes: A
legitimate platform for the signaling train. Proc. Natl. Acad. Sci. U.S.A. 106, 17615–17622
(2009).
9. K. A. DeFea, Z. D. Vaughn, E. M. O'Bryan, D. Nishijima, O. Déry, N. W. Bunnett, The
proliferative and antiapoptotic effects of substance P are facilitated by formation of a
b-arrestin-dependent scaffolding complex. Proc. Natl. Acad. Sci. U.S.A. 97, 11086–11091
(2000).
10. K. A. DeFea, J. Zalevsky, M. S. Thoma, O. Déry, R. D. Mullins, N. W. Bunnett, b-Arrestin–
dependent endocytosis of proteinase-activated receptor 2 is required for intracellular
targeting of activated ERK1/2. J. Cell Biol. 148, 1267–1281 (2000).
11. D. Calebiro, V. O. Nikolaev, M. C. Gagliani, T. de Filippis, C. Dees, C. Tacchetti, L. Persani,
M. J. Lohse, Persistent cAMP-signals triggered by internalized G-protein–coupled
receptors. PLOS Biol. 7, e1000172 (2009).
12. R. Irannejad, J. C. Tomshine, J. R. Tomshine, M. Chevalier, J. P. Mahoney, J. Steyaert,
S. G. F. Rasmussen, R. K. Sunahara, H. El-Samad, B. Huang, M. von Zastrow, Conformational
biosensors reveal GPCR signalling from endosomes. Nature 495, 534–538 (2013).13 of 15
SC I ENCE TRANS LAT IONAL MED I C I N E | R E S EARCH ART I C L E13. A. R. B. Thomsen, B. Plouffe, T. J. Cahill III, A. K. Shukla, J. T. Tarrasch, A. M. Dosey,
A. W. Kahsai, R. T. Strachan, B. Pani, J. P. Mahoney, L. Huang, B. Breton, F. M. Heydenreich,
R. K. Sunahara, G. Skiniotis, M. Bouvier, R. J. Lefkowitz, GPCR-G protein-b-arrestin super-
complex mediates sustained G protein signaling. Cell 166, 907–919 (2016).
14. P. W. Mantyh, E. DeMaster, A. Malhotra, J. R. Ghilardi, S. D. Rogers, C. R. Mantyh, H. Liu,
A. I. Basbaum, S. R. Vigna, J. E. Maggio, D. A. Simone, Receptor endocytosis and
dendrite reshaping in spinal neurons after somatosensory stimulation. Science 268,
1629–1632 (1995).
15. J. M. Jarcho, N. A. Feier, A. Bert, J. A. Labus, M. Lee, J. Stains, B. Ebrat, S. M. Groman,
K. Tillisch, A. L. Brody, E. D. London, M. A. Mandelkern, E. A. Mayer, Diminished
neurokinin-1 receptor availability in patients with two forms of chronic visceral pain.
Pain 154, 987–996 (2013).
16. K. McConalogue, O. Déry, M. Lovett, H. Wong, J. H. Walsh, E. F. Grady, N. W. Bunnett,
Substance P-induced trafficking of b-arrestins. The role of b-arrestins in endocytosis of
the neurokinin-1 receptor. J. Biol. Chem. 274, 16257–16268 (1999).
17. M. J. Robertson, F. M. Deane, P. J. Robinson, A. McCluskey, Synthesis of Dynole 34-2,
Dynole 2-24 and Dyngo 4a for investigating dynamin GTPase. Nat. Protoc. 9, 851–870
(2014).
18. M. J. Robertson, F. M. Deane, W. Stahlschmidt, L. von Kleist, V. Haucke, P. J. Robinson,
A. McCluskey, Synthesis of the Pitstop family of clathrin inhibitors. Nat. Protoc. 9,
1592–1606 (2014).
19. F. Schmidlin, O. Déry, K. O. DeFea, L. Slice, S. Patierno, C. Sternini, E. F. Grady,
N. W. Bunnett, Dynamin and Rab5a-dependent trafficking and signaling of the
neurokinin 1 receptor. J. Biol. Chem. 276, 25427–25437 (2001).
20. M. L. Halls, D. P. Poole, A. M. Ellisdon, C. J. Nowell, M. Canals, Detection and quantification
of intracellular signaling using FRET-based biosensors and high content imaging.
Methods Mol. Biol. 1335, 131–161 (2015).
21. N. G. Tsvetanova, R. Irannejad, M. von Zastrow, G protein-coupled receptor (GPCR)
signaling via heterotrimeric G proteins from endosomes. J. Biol. Chem. 290, 6689–6696
(2015).
22. G. S. Cottrell, B. E. Padilla, S. Amadesi, D. P. Poole, J. E. Murphy, M. Hardt, D. Roosterman,
M. Steinhoff, N. W. Bunnett, Endosomal endothelin-converting enzyme-1: A regulator
of b-arrestin-dependent ERK signaling. J. Biol. Chem. 284, 22411–22425 (2009).
23. D. D. Jensen, M. L. Halls, J. E. Murphy, M. Canals, F. Cattaruzza, D. P. Poole, T. Lieu,
H.-W. Koon, C. Pothoulakis, N. W. Bunnett, Endothelin-converting enzyme 1 and
b-arrestins exert spatiotemporal control of substance P-induced inflammatory signals.
J. Biol. Chem. 289, 20283–20294 (2014).
24. S. P. Davies, H. Reddy, M. Caivano, P. Cohen, Specificity and mechanism of action of some
commonly used protein kinase inhibitors. Biochem. J. 351, 95–105 (2000).
25. R.-R. Ji, K. Befort, G. J. Brenner, C. J. Woolf, ERK MAP kinase activation in superficial spinal cord
neurons induces prodynorphin and NK-1 upregulation and contributes to persistent
inflammatory pain hypersensitivity. J. Neurosci. 22, 478–485 (2002).
26. K. Murase, M. Randić, Actions of substance P on rat spinal dorsal horn neurones. J. Physiol.
346, 203–217 (1984).
27. X. Emonds-Alt, J. D. Doutremepuich, M. Heaulme, G. Neliat, V. Santucci, R. Steinberg,
P. Vilain, D. Bichon, J.-P. Ducoux, V. Proietto, D. Van Broeck, P. Soubrié, G. Le Fu,
J.-C. Breliére, In vitro and in vivo biological activities of SR140333, a novel potent non-
peptide tachykinin NK1 receptor antagonist. Eur. J. Pharmacol. 250, 403–413 (1993).
28. D. Roosterman, G. S. Cottrell, F. Schmidlin, M. Steinhoff, N. W. Bunnett, Recycling and
resensitization of the neurokinin 1 receptor. Influence of agonist concentration and Rab
GTPases. J. Biol. Chem. 279, 30670–30679 (2004).
29. D. Roosterman, G. S. Cottrell, B. E. Padilla, L. Muller, C. B. Eckman, N. W. Bunnett,
M. Steinhoff, Endothelin-converting enzyme 1 degrades neuropeptides in endosomes to
control receptor recycling. Proc. Natl. Acad. Sci. U.S.A. 104, 11838–11843 (2007).
30. P. Y. Sato, J. K. Chuprun, M. Schwartz, W. J. Koch, The evolving impact of G protein-
coupled receptor kinases in cardiac health and disease. Phys. Rev. 95, 377–404 (2015).
31. L. Rajendran, V. Udayar, Z. V. Goodger, Lipid-anchored drugs for delivery into subcellular
compartments. Trends Pharmacol. Sci. 33, 215–222 (2012).
32. K. Folkers, R. Håkanson, J. Hörig, J.-C. Xu, S. Leander, Biological evaluation of substance P
antagonists. Br. J. Pharmacol. 83, 449–456 (1984).
33. N. M. Rupniak, E. Carlson, S. Boyce, J. K. Webb, R. G. Hill, Enantioselective inhibition of the
formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain 67,
189–195 (1996).
34. J. A. Heymann, J. E. Hinshaw, Dynamins at a glance. J. Cell Sci. 122, 3427–3431 (2009).
35. H. T. McMahon, E. Boucrot, Molecular mechanism and physiological functions of clathrin-
mediated endocytosis. Nat. Rev. Mol. Cell Biol. 12, 517–533 (2011).
36. R. J. Park, H. Shen, L. Liu, X. Liu, S. M. Ferguson, P. De Camilli, Dynamin triple knockout
cells reveal off target effects of commonly used dynamin inhibitors. J. Cell Sci. 126,
5305–5312 (2013).
37. M. Kocan, M. B. Dalrymple, R. M. Seeber, B. J. Feldman, K. D. G. Pfleger, Enhanced BRET
technology for the monitoring of agonist-induced and agonist-independent interactions
between GPCRs and b-arrestins. Front. Endocrinol. 1, 12 (2010).Jensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 201738. T.-H. Lan, Q. Liu, C. Li, G. Wu, N. A. Lambert, Sensitive and high resolution localization
and tracking of membrane proteins in live cells with BRET. Traffic 13, 1450–1456
(2012).
39. C. D. Harvey, A. G. Ehrhardt, C. Cellurale, H. Zhong, R. Yasuda, R. J. Davis, K. Svoboda, A
genetically encoded fluorescent sensor of ERK activity. Proc. Natl. Acad. Sci. U.S.A. 105,
19264–19269 (2008).
40. J. D. Violin, J. Zhang, R. Y. Tsien, A. C. Newton, A genetically encoded fluorescent
reporter reveals oscillatory phosphorylation by protein kinase C. J. Cell Biol. 161,
899–909 (2003).
41. V. O. Nikolaev, M. Bünemann, L. Hein, A. Hannawacker, M. J. Lohse, Novel single chain
cAMP sensors for receptor-induced signal propagation. J. Biol. Chem. 279, 37215–37218
(2004).
42. S. Wachten, N. Masada, L. J. Ayling, A. Ciruela, V. O. Nikolaev, M. J. Lohse, D. M. Cooper,
Distinct pools of cAMP centre on different isoforms of adenylyl cyclase in pituitary-
derived GH3B6 cells. J. Cell Sci. 123, 95–106 (2010).
43. O. Déry, K. A. Defea, N. W. Bunnett, Protein kinase C-mediated desensitization of the
neurokinin 1 receptor. Am. J. Physiol. Cell Physiol. 280, C1097–C1106 (2001).
44. M. L. Halls, R. A. D. Bathgate, R. J. Summers, Comparison of signaling pathways activated
by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes.
J. Pharmacol. Exp. Ther. 320, 281–290 (2007).
45. X. H. Yu, A. Ribeiro-da-Silva, Y. De Koninck, Morphology and neurokinin 1 receptor
expression of spinothalamic lamina I neurons in the rat spinal cord. J. Comp. Neurol. 491,
56–68 (2005).
46. W. L. Imlach, R. F. Bhola, L. T. May, A. Christopoulos, M. J. Christie, A positive allosteric
modulator of the adenosine A1 receptor selectively inhibits primary afferent synaptic
transmission in a neuropathic pain model. Mol. Pharm. 88, 460–468 (2015).
47. S. Amadesi, J. Nie, N. Vergnolle, G. S. Cottrell, E. F. Grady, M. Trevisani, C. Manni,
P. Geppetti, J. A. McRoberts, H. Ennes, J. B. Davis, E. A. Mayer, N. W. Bunnett, Protease-
activated receptor 2 sensitizes the capsaicin receptor transient receptor potential
vanilloid receptor 1 to induce hyperalgesia. J. Neurosci. 24, 4300–4312 (2004).
48. E. F. Grady, P. Baluk, S. Böhm, P. D. Gamp, H. Wong, D. G. Payan, J. Ansel, A. L. Portbury,
J. B. Furness, D. M. McDonald, N. W. Bunnett, Characterization of antisera specific to
NK1, NK2, and NK3 neurokinin receptors and their utilization to localize receptors in the
rat gastrointestinal tract. J. Neurosci. 16, 6975–6986 (1996).
49. F. Alemi, E. Kwon, D. P. Poole, T. Lieu, V. Lyo, F. Cattaruzza, F. Cevikbas, M. Steinhoff,
R. Nassini, S. Materazzi, R. Guerrero-Alba, E. Valdez-Morales, G. S. Cottrell, K. Schoonjans,
P. Geppetti, S. J. Vanner, N. W. Bunnett, C. U. Corvera, The TGR5 receptor mediates bile
acid-induced itch and analgesia. J. Clin. Invest. 123, 1513–1530 (2013).
50. D. P. Poole, S. Amadesi, N. A. Veldhuis, F. C. Abogadie, T. Lieu, W. Darby, W. Liedtke,
M. J. Lew, P. McIntyre, N. W. Bunnett, Protease-activated receptor 2 (PAR2) protein and
transient receptor potential vanilloid 4 (TRPV4) protein coupling is required for sustained
inflammatory signaling. J. Biol. Chem. 288, 5790–5802 (2013).
51. A. Schlegel, C. Largeau, P. Bigey, M. Bessodes, K. Lebozec, D. Scherman, V. Escriou, Anionic
polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed
with cationic liposomes. J. Control Release 152, 393–401 (2011).
52. M. Fa, A. Staniszewski, F. Saeed, Y. I. Francis, O. Arancio, Dynamin 1 is required for
memory formation. PLOS ONE 9, e91954 (2014).
53. T. C. Tan, V. A. Valova, C. S. Malladi, M. E. Graham, L. A. Berven, O. J. Jupp, G. Hansra,
S. J. McClure, B. Sarcevic, R. A. Boadle, M. R. Larsen, M. A. Cousin, P. J. Robinson, Cdk5 is
essential for synaptic vesicle endocytosis. Nat. Cell Biol. 5, 701–710 (2003).
54. N. W. Bunnett, R. Kobayashi, M. S. Orloff, J. R. Reeve, A. J. Turner, J. H. Walsh, Catabolism of
gastrin releasing peptide and substance P by gastric membrane-bound peptidases.
Peptides 6, 277–283 (1985).
Acknowledgments: We thank C. Nowell for image analysis and F. Chiu for analysis of probe
degradation. Funding: This work was supported by National Health and Medical Research
Council (NHMRC) grants 63303, 1049682, and 1031886; the Australia Research Council Centre
of Excellence in Convergent Bio-Nano Science and Technology; and Monash University (to
N.W.B.); by NHMRC grants 1047070, 1032771, 1022218, 1017063, and 1011457; the Australian
Cancer Research Foundation; and the Ramaciotti Foundation (to P.J.R. and A.M.); and by
Takeda Pharmaceuticals Inc. M.L.H. is an NHMRC R.D. Wright Career Development Fellow
(1061687) and M.C. is a Monash Fellow. Author contributions: D.D.J. analyzed NK1R
trafficking; T.L. studied nociception, inflammation, and motor functions; M.L.H. designed
and completed FRET analyses of compartmentalized signaling; N.A.V. studied subcellular
trafficking of tripartite probes and FRET analysis of probe/receptor interactions; W.L.I. analyzed
excitation of spinal neurons by electrophysiology; Q.N.M. studied subcellular trafficking of
tripartite probes; D.P.P. examined NK1R trafficking by confocal microscopy; T.Q. synthesized
and purified tripartite probes; L.A. synthesized and purified tripartite probes; J.C. synthesized
and purified tripartite probes; C.K.H. analyzed transcription; N.B. synthesized and purified
fluorescent SP; J.S.S. designed tripartite probes; M.J.S. conceived and designed the studies to
use tripartite probes to therapeutically target endosomal receptors; B.G. designed tripartite14 of 15
SC I ENCE TRANS LAT IONAL MED I C I N E | R E S EARCH ART I C L Eprobes; A.M. designed and synthesized inhibitors of endocytosis and inactive control analogs;
P.J.R. designed and characterized inhibitors of endocytosis; V.E. designed and prepared
cationic liposome and anionic polymer adjuvant for in vivo delivery of siRNA; R.N. measured
neuropeptide release from spinal cord; S.M. measured neuropeptide release from spinal
cord; P.G. conceived, designed, and analyzed studies to examine neuropeptide release from
nociceptors; G.A.H. conceived the studies; M.J.C. conceived, designed, and analyzed studies
of excitation of spinal neurons; C.J.H.P. conceived and designed the studies to use tripartite
probes to therapeutically target endosomal receptors; M.C. conceived, designed, and
completed all BRET analyses of subcellular NK1R trafficking and G protein activation; and
N.W.B. conceived the studies, designed experiments, interpreted the results, and wrote the
manuscript. Competing interests: Work at N.W.B.’s laboratory was funded, in part, by Takeda
Pharmaceuticals Inc. N.W.B. has filed a patent for use of lipidation to target GPCRs in
endosomes. All other authors declare that they have no competing interests. Materials and
data availability: Plasmids encoding the FRET biosensors Epac-camps are available from
M. J. Lohse under a material transfer agreement with the University of Wurzburg. PlasmidsJensen et al., Sci. Transl. Med. 9, eaal3447 (2017) 31 May 2017encoding the FRET biosensors cytoplasmic EKAR and nuclear EKAR are available under a
material transfer agreement with Addgene. Dy4 is available from A.M. under a material
transfer agreement with the University of Newcastle.
Submitted 4 November 2016
Accepted 17 March 2017
Published 31 May 2017
10.1126/scitranslmed.aal3447
Citation: D. D. Jensen, T. Lieu, M. L. Halls, N. A. Veldhuis, W. L. Imlach, Q. N. Mai, D. P. Poole,
T. Quach, L. Aurelio, J. Conner, C. K. Herenbrink, N. Barlow, J. S. Simpson, M. J. Scanlon,
B. Graham, A. McCluskey, P. J. Robinson, V. Escriou, R. Nassini, S. Materazzi, P. Geppetti,
G. A. Hicks, M. J. Christie, C. J. H. Porter, M. Canals, N. W. Bunnett, Neurokinin 1 receptor
signaling in endosomes mediates sustained nociception and is a viable therapeutic target
for prolonged pain relief. Sci. Transl. Med. 9, eaal3447 (2017).15 of 15
